Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia
- 31 July 1990
- journal article
- Published by Elsevier BV in Atherosclerosis
- Vol. 83 (1), 89-97
- https://doi.org/10.1016/0021-9150(90)90134-5
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Interaction between low density lipoprotein receptor (LDLR) and apolipoprotein E (apoE) alleles contributes to normal variation in lipid levelClinical Genetics, 1989
- Apolipoprotein E polymorphism in the Netherlands and its effect on plasma lipid and apolipoprotein levelsHuman Genetics, 1988
- Familial hypercholesterolemia and apolipoprotein E4Atherosclerosis, 1988
- Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemiaAtherosclerosis, 1988
- Apolipoprotein E polymorphism in health and diseaseAmerican Heart Journal, 1987
- A Receptor-Mediated Pathway for Cholesterol HomeostasisScience, 1986
- Receptor-Mediated Endocytosis: Concepts Emerging from the LDL Receptor SystemAnnual Review of Cell Biology, 1985
- Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modificationBiochemistry, 1981
- Polymorphism of apolipoprotein EClinical Genetics, 1979
- Familial hyperlipoproteinemia type III: Deficiency of a specific apolipoprotein (APO E‐III) in the very‐low‐density lipoproteinsFEBS Letters, 1975